{"id":8369,"date":"2026-06-10T08:00:11","date_gmt":"2026-06-10T06:00:11","guid":{"rendered":"https:\/\/www.iqac.csic.es\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\/"},"modified":"2026-06-16T10:47:44","modified_gmt":"2026-06-16T08:47:44","slug":"un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic","status":"publish","type":"post","link":"https:\/\/www.iqac.csic.es\/ca\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\/","title":{"rendered":"Un f\u00e0rmac redueix el risc de desenvolupar artritis reumatoide, segons un assaig cl\u00ednic"},"content":{"rendered":"<p>&nbsp;<\/p>\n<\/div>\n<p>Un assaig cl\u00ednic liderat per professionals de l\u2019Hospital Cl\u00ednic de Barcelona, l\u2019Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS) i l\u2019Institut de Qu\u00edmica Avan\u00e7ada de Catalunya (IQAC-CSIC) ha comparat l\u2019efic\u00e0cia dels f\u00e0rmacs abatacept i hidroxicloroquina per prevenir el desenvolupament de l\u2019artritis reumatoide en pacients amb reumatisme palindr\u00f2mic, una malaltia autoimmune que evoluciona cap a l\u2019artritis en aproximadament la meitat dels pacients. L\u2019assaig cl\u00ednic s\u2019ha desenvolupat durant dos anys en 14 hospitals de tot Espanya amb la participaci\u00f3 de 70 pacients amb reumatisme palindr\u00f2mic. Els resultats, publicats a la revista <a href=\"https:\/\/www.nature.com\/articles\/s41591-026-04395-6\" target=\"_blank\" rel=\"noopener\"><em>Nature Medicine<\/em><\/a>, indiquen que l\u2019abatacept \u00e9s significativament m\u00e9s efica\u00e7 que la hidroxicloroquina per prevenir el desenvolupament de l\u2019artritis.<\/p>\n<p>El reumatisme palindr\u00f2mic \u00e9s una malaltia caracteritzada per episodis intermitents d\u2019inflamaci\u00f3 articular amb crisis agudes que duren pocs dies i que es resolen espont\u00e0niament. Tanmateix, aproximadament la meitat dels pacients acaben desenvolupant artritis reumatoide, una malaltia cr\u00f2nica que causa dany articular irreversible. Aquest factor de risc \u00e9s especialment elevat en persones amb biomarcadors com el factor reumatoide i els anticossos contra p\u00e8ptids citrulinats. La pres\u00e8ncia d\u2019aquests dos autoanticossos \u2014prote\u00efnes del sistema immunitari que ataquen per error \u00f2rgans i teixits de l\u2019organisme\u2014 serveix per al diagn\u00f2stic de la malaltia.<\/p>\n<p>Fins ara, en abs\u00e8ncia d\u2019assaigs cl\u00ednics, l\u2019estrat\u00e8gia habitual consistia a tractar els pacients amb reumatisme palindr\u00f2mic amb hidroxicloroquina, un f\u00e0rmac amb propietats antiinflamat\u00f2ries i immunosupressores amb el qual es busca millorar els s\u00edmptomes de la malaltia. En aquest context, l\u2019equip liderat per <strong>Raimon Sanmart\u00ed<\/strong>, cap del grup de recerca en Artropaties Inflamat\u00f2ries de l\u2019IDIBAPS, ha impulsat un assaig cl\u00ednic de dos anys amb 70 pacients amb reumatisme palindr\u00f2mic. L\u2019objectiu era comparar l\u2019efic\u00e0cia de la hidroxicloroquina amb la de l\u2019abatacept, un inhibidor dels limf\u00f2cits \u2014un tipus de gl\u00f2bul blanc que ataca les articulacions en confondre-les amb una amena\u00e7a\u2014, per reduir la progressi\u00f3 del reumatisme palindr\u00f2mic cap a l\u2019artritis reumatoide.<\/p>\n<p>Els resultats demostren que el tractament amb abatacept redueix de manera significativa la progressi\u00f3 cap a l\u2019artritis reumatoide. Amb aquest f\u00e0rmac, nom\u00e9s el 20% dels pacients acaben desenvolupant artritis, en comparaci\u00f3 amb el 50% dels tractats amb hidroxicloroquina. A m\u00e9s, els pacients tractats amb abatacept no nom\u00e9s eviten la progressi\u00f3 cap a l\u2019artritis reumatoide en la majoria dels casos, sin\u00f3 que tamb\u00e9 presenten una millora significativa dels s\u00edmptomes del reumatisme palindr\u00f2mic. \u00abL\u2019estudi mostra que els pacients amb reumatisme tractats amb abatacept aconsegueixen amb m\u00e9s freq\u00fc\u00e8ncia la remissi\u00f3 completa de les crisis associades a dolor agut i inflor articular, i que els seus episodis inflamatoris s\u00f3n menys intensos\u00bb, explica <strong>Isabel Haro<\/strong>, cap de la Unitat de S\u00edntesi i Aplicacions Biom\u00e8diques de P\u00e8ptids de l\u2019IQAC-CSIC. L\u2019equip investigador destaca que tots dos f\u00e0rmacs van ser segurs i ben tolerats durant l\u2019assaig cl\u00ednic.<\/p>\n<h4>Una intervenci\u00f3 preco\u00e7<\/h4>\n<p>\u201cEls resultats d\u2019aquest estudi indiquen que podem intervenir de manera preco\u00e7 per modificar el curs natural de la malaltia i reduir el risc que els pacients desenvolupin malalties m\u00e9s greus i irreversibles\u201d, explica Sanmart\u00ed. \u201cAix\u00f2 obre la porta a un canvi de paradigma en el tractament d\u2019aquests pacients\u201d.<\/p>\n<blockquote><p>L\u2019estudi, que compta amb la participaci\u00f3 de diversos centres nacionals, tamb\u00e9 va analitzar l\u2019evoluci\u00f3 de diversos biomarcadors (autoanticossos) desenvolupats pel grup de recerca del CSIC en el seguiment dels pacients. \u00abTot i que no es van observar difer\u00e8ncies significatives entre l\u2019abatacept i la hidroxicloroquina en la resposta dels autoanticossos, aquest treball demostra el valor dels enfocaments immunomoduladors en fases inicials de la malaltia, quan encara \u00e9s possible evitar la progressi\u00f3 cap a formes m\u00e9s greus i cr\u00f2niques\u00bb, assenyala Haro.<\/p><\/blockquote>\n<p>L\u2019artritis reumatoide \u00e9s una malaltia que afecta la qualitat de vida dels pacients i suposa una elevada c\u00e0rrega per als sistemes sanitaris. Poder prevenir-ne el desenvolupament en una proporci\u00f3 significativa dels casos representa un aven\u00e7 important en l\u2019abordatge de les malalties reum\u00e0tiques.<\/p>\n<p>&nbsp;<\/p>\n<p style=\"font-size: 75%;\">Raimon Sanmarti, Carolina P\u00e9rez-Garc\u00eda, Francisco J. de-Toro, Georgina Salvador, Alejandro Escudero Contreras, Andrea Cuervo, Eduard Graell, Delia Reina, Eduardo Kanterewicz et al. <strong>Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial<\/strong>. <em>Nature Medicine<\/em>. DOI: <a href=\"https:\/\/www.nature.com\/articles\/s41591-026-04395-6\" target=\"_blank\" rel=\"noopener\">doi.org\/10.1038\/s41591-026-04395-6<\/a><\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: right;\"><strong>IQAC-CSIC Comunicaci\u00f3<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; Un assaig cl\u00ednic liderat per professionals de l\u2019Hospital Cl\u00ednic de Barcelona, l\u2019Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS) i l\u2019Institut de Qu\u00edmica Avan\u00e7ada de Catalunya (IQAC-CSIC) ha comparat l\u2019efic\u00e0cia dels f\u00e0rmacs abatacept i hidroxicloroquina per prevenir el desenvolupament de l\u2019artritis reumatoide en pacients amb reumatisme palindr\u00f2mic, una malaltia autoimmune que evoluciona cap a<a class=\"more-link\" href=\"https:\/\/www.iqac.csic.es\/ca\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\/\">Continue reading <span class=\"screen-reader-text\">\u00abUn f\u00e0rmac redueix el risc de desenvolupar artritis reumatoide, segons un assaig cl\u00ednic\u00bb<\/span><\/a><\/p>\n","protected":false},"author":3,"featured_media":4614,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[73],"tags":[],"class_list":["post-8369","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Un f\u00e0rmac redueix el risc de desenvolupar artritis reumatoide, segons un assaig cl\u00ednic | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.iqac.csic.es\/ca\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Un f\u00e0rmac redueix el risc de desenvolupar artritis reumatoide, segons un assaig cl\u00ednic | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\" \/>\n<meta property=\"og:description\" content=\"&nbsp; Un assaig cl\u00ednic liderat per professionals de l\u2019Hospital Cl\u00ednic de Barcelona, l\u2019Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS) i l\u2019Institut de Qu\u00edmica Avan\u00e7ada de Catalunya (IQAC-CSIC) ha comparat l\u2019efic\u00e0cia dels f\u00e0rmacs abatacept i hidroxicloroquina per prevenir el desenvolupament de l\u2019artritis reumatoide en pacients amb reumatisme palindr\u00f2mic, una malaltia autoimmune que evoluciona cap aContinue reading &quot;Un f\u00e0rmac redueix el risc de desenvolupar artritis reumatoide, segons un assaig cl\u00ednic&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.iqac.csic.es\/ca\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\/\" \/>\n<meta property=\"og:site_name\" content=\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/iqac.csic.es\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-10T06:00:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-16T08:47:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/06\/artritisreumatoide_istock.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1254\" \/>\n\t<meta property=\"og:image:height\" content=\"836\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Ana Sotres\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@IQAC_CSIC\" \/>\n<meta name=\"twitter:site\" content=\"@IQAC_CSIC\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ana Sotres\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/ca\\\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/ca\\\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\\\/\"},\"author\":{\"name\":\"Ana Sotres\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#\\\/schema\\\/person\\\/ac65d00561d3a6d2810128c46771aff7\"},\"headline\":\"Un f\u00e0rmac redueix el risc de desenvolupar artritis reumatoide, segons un assaig cl\u00ednic\",\"datePublished\":\"2026-06-10T06:00:11+00:00\",\"dateModified\":\"2026-06-16T08:47:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/ca\\\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\\\/\"},\"wordCount\":767,\"publisher\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/ca\\\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.iqac.csic.es\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/artritisreumatoide_istock.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/ca\\\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\\\/\",\"url\":\"https:\\\/\\\/www.iqac.csic.es\\\/ca\\\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\\\/\",\"name\":\"Un f\u00e0rmac redueix el risc de desenvolupar artritis reumatoide, segons un assaig cl\u00ednic | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/ca\\\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/ca\\\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.iqac.csic.es\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/artritisreumatoide_istock.jpg\",\"datePublished\":\"2026-06-10T06:00:11+00:00\",\"dateModified\":\"2026-06-16T08:47:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/ca\\\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\\\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.iqac.csic.es\\\/ca\\\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/ca\\\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.iqac.csic.es\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/artritisreumatoide_istock.jpg\",\"contentUrl\":\"https:\\\/\\\/www.iqac.csic.es\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/artritisreumatoide_istock.jpg\",\"width\":1254,\"height\":836},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/ca\\\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/www.iqac.csic.es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Un f\u00e0rmac redueix el risc de desenvolupar artritis reumatoide, segons un assaig cl\u00ednic\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#website\",\"url\":\"https:\\\/\\\/www.iqac.csic.es\\\/\",\"name\":\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\",\"description\":\"Chemistry for a better life\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#organization\"},\"alternateName\":\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.iqac.csic.es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#organization\",\"name\":\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\",\"alternateName\":\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\",\"url\":\"https:\\\/\\\/www.iqac.csic.es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.iqac.csic.es\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/cropped-favicon-1.png\",\"contentUrl\":\"https:\\\/\\\/www.iqac.csic.es\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/cropped-favicon-1.png\",\"width\":512,\"height\":512,\"caption\":\"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC\"},\"image\":{\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/iqac.csic.es\\\/\",\"https:\\\/\\\/x.com\\\/IQAC_CSIC\",\"https:\\\/\\\/www.instagram.com\\\/iqac_csic\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UC1JXTOe3-s8UnYu_A6-SI3A\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/iqac-csic\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.iqac.csic.es\\\/#\\\/schema\\\/person\\\/ac65d00561d3a6d2810128c46771aff7\",\"name\":\"Ana Sotres\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/25826e5f3a7a258c44e58bdd075d81df4fb82260d2ac4db8eb7f8a34fe10b563?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/25826e5f3a7a258c44e58bdd075d81df4fb82260d2ac4db8eb7f8a34fe10b563?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/25826e5f3a7a258c44e58bdd075d81df4fb82260d2ac4db8eb7f8a34fe10b563?s=96&d=mm&r=g\",\"caption\":\"Ana Sotres\"},\"sameAs\":[\"https:\\\/\\\/www.iqac.csic.es\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Un f\u00e0rmac redueix el risc de desenvolupar artritis reumatoide, segons un assaig cl\u00ednic | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.iqac.csic.es\/ca\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\/","og_locale":"ca_ES","og_type":"article","og_title":"Un f\u00e0rmac redueix el risc de desenvolupar artritis reumatoide, segons un assaig cl\u00ednic | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","og_description":"&nbsp; Un assaig cl\u00ednic liderat per professionals de l\u2019Hospital Cl\u00ednic de Barcelona, l\u2019Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS) i l\u2019Institut de Qu\u00edmica Avan\u00e7ada de Catalunya (IQAC-CSIC) ha comparat l\u2019efic\u00e0cia dels f\u00e0rmacs abatacept i hidroxicloroquina per prevenir el desenvolupament de l\u2019artritis reumatoide en pacients amb reumatisme palindr\u00f2mic, una malaltia autoimmune que evoluciona cap aContinue reading \"Un f\u00e0rmac redueix el risc de desenvolupar artritis reumatoide, segons un assaig cl\u00ednic\"","og_url":"https:\/\/www.iqac.csic.es\/ca\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\/","og_site_name":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","article_publisher":"https:\/\/www.facebook.com\/iqac.csic.es\/","article_published_time":"2026-06-10T06:00:11+00:00","article_modified_time":"2026-06-16T08:47:44+00:00","og_image":[{"width":1254,"height":836,"url":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/06\/artritisreumatoide_istock.jpg","type":"image\/jpeg"}],"author":"Ana Sotres","twitter_card":"summary_large_image","twitter_creator":"@IQAC_CSIC","twitter_site":"@IQAC_CSIC","twitter_misc":{"Escrit per":"Ana Sotres","Temps estimat de lectura":"4 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.iqac.csic.es\/ca\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\/#article","isPartOf":{"@id":"https:\/\/www.iqac.csic.es\/ca\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\/"},"author":{"name":"Ana Sotres","@id":"https:\/\/www.iqac.csic.es\/#\/schema\/person\/ac65d00561d3a6d2810128c46771aff7"},"headline":"Un f\u00e0rmac redueix el risc de desenvolupar artritis reumatoide, segons un assaig cl\u00ednic","datePublished":"2026-06-10T06:00:11+00:00","dateModified":"2026-06-16T08:47:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.iqac.csic.es\/ca\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\/"},"wordCount":767,"publisher":{"@id":"https:\/\/www.iqac.csic.es\/#organization"},"image":{"@id":"https:\/\/www.iqac.csic.es\/ca\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\/#primaryimage"},"thumbnailUrl":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/06\/artritisreumatoide_istock.jpg","articleSection":["News"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/www.iqac.csic.es\/ca\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\/","url":"https:\/\/www.iqac.csic.es\/ca\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\/","name":"Un f\u00e0rmac redueix el risc de desenvolupar artritis reumatoide, segons un assaig cl\u00ednic | IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","isPartOf":{"@id":"https:\/\/www.iqac.csic.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.iqac.csic.es\/ca\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\/#primaryimage"},"image":{"@id":"https:\/\/www.iqac.csic.es\/ca\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\/#primaryimage"},"thumbnailUrl":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/06\/artritisreumatoide_istock.jpg","datePublished":"2026-06-10T06:00:11+00:00","dateModified":"2026-06-16T08:47:44+00:00","breadcrumb":{"@id":"https:\/\/www.iqac.csic.es\/ca\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.iqac.csic.es\/ca\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.iqac.csic.es\/ca\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\/#primaryimage","url":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/06\/artritisreumatoide_istock.jpg","contentUrl":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2026\/06\/artritisreumatoide_istock.jpg","width":1254,"height":836},{"@type":"BreadcrumbList","@id":"https:\/\/www.iqac.csic.es\/ca\/un-farmac-redueix-el-risc-de-desenvolupar-artritis-reumatoide-segons-un-assaig-clinic\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/www.iqac.csic.es\/"},{"@type":"ListItem","position":2,"name":"Un f\u00e0rmac redueix el risc de desenvolupar artritis reumatoide, segons un assaig cl\u00ednic"}]},{"@type":"WebSite","@id":"https:\/\/www.iqac.csic.es\/#website","url":"https:\/\/www.iqac.csic.es\/","name":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","description":"Chemistry for a better life","publisher":{"@id":"https:\/\/www.iqac.csic.es\/#organization"},"alternateName":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.iqac.csic.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.iqac.csic.es\/#organization","name":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","alternateName":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC","url":"https:\/\/www.iqac.csic.es\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.iqac.csic.es\/#\/schema\/logo\/image\/","url":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2025\/11\/cropped-favicon-1.png","contentUrl":"https:\/\/www.iqac.csic.es\/wp-content\/uploads\/2025\/11\/cropped-favicon-1.png","width":512,"height":512,"caption":"IQAC - Institut de Qu\u00edmica Avan\u00e7ada de Catalunya - CSIC"},"image":{"@id":"https:\/\/www.iqac.csic.es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/iqac.csic.es\/","https:\/\/x.com\/IQAC_CSIC","https:\/\/www.instagram.com\/iqac_csic","https:\/\/www.youtube.com\/channel\/UC1JXTOe3-s8UnYu_A6-SI3A","https:\/\/www.linkedin.com\/company\/iqac-csic\/"]},{"@type":"Person","@id":"https:\/\/www.iqac.csic.es\/#\/schema\/person\/ac65d00561d3a6d2810128c46771aff7","name":"Ana Sotres","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/secure.gravatar.com\/avatar\/25826e5f3a7a258c44e58bdd075d81df4fb82260d2ac4db8eb7f8a34fe10b563?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/25826e5f3a7a258c44e58bdd075d81df4fb82260d2ac4db8eb7f8a34fe10b563?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/25826e5f3a7a258c44e58bdd075d81df4fb82260d2ac4db8eb7f8a34fe10b563?s=96&d=mm&r=g","caption":"Ana Sotres"},"sameAs":["https:\/\/www.iqac.csic.es\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/posts\/8369","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/comments?post=8369"}],"version-history":[{"count":1,"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/posts\/8369\/revisions"}],"predecessor-version":[{"id":8529,"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/posts\/8369\/revisions\/8529"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/media\/4614"}],"wp:attachment":[{"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/media?parent=8369"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/categories?post=8369"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.iqac.csic.es\/ca\/wp-json\/wp\/v2\/tags?post=8369"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}